WILMINGTON, NC – (COMMERCIAL THREAD) – PPD, Inc. (Nasdaq: PPD) was recognized for the 10e consecutive year as one of America’s leading companies for employee learning and development. PPD was appointed to Coaching the magazine’s Top 100 list, which recognizes companies that demonstrate measurable results of effective employee learning and development linked to strategic goals.
âEarn this recognition for the 10e year in a row underscores PPD’s commitment to effective employee training and development results that deliver tangible benefits to our customers and their drug development initiatives, âsaid Jay Dixon, senior vice president of quality and corporate learning at PPD. âOur learning culture helps make PPD a great company to work for and helps increase employee engagement and retention, improving the continuity of our clients’ important research programs. ”
To view a video of Dixon reflecting on this achievement, visit http://bit.ly/3ptYwxQ.
PPD designs, develops and deploys a wide range of employee learning and performance programs, providing continuous training and development that engage employees for peak performance, leverage technology, develop people and measure results.
âPPD’s learning strategy is directly linked to business goals and is laser-focused to help its business meet its critical priorities,â said Lorri Freifeld, Coaching editor of the magazine. âOver the past year, the company has launched skills upgrading initiatives as part of flagship projects to improve the performance of the thousands of its employees performing clinical trials. PPD training draws on cutting-edge technology, measurement methods and collaboration for optimal learner experience and engagement.
This year marks a milestone for PPD as it is the highest ranking the company has received on Coaching list of magazines. Training rankings are based on a variety of benchmarking statistics, such as total training budget; percentage of payroll; number of training hours per program employed; workplace goals, evaluation, measurement and surveys; training hours per employee annually; and detailed official programs.
Employee learning and development at PPD includes high potential leadership and development, key talent programs, technical skills, job specific training and soft skills training of individual contributors, all integrated and aligned with company goals and objectives. These initiatives are driven from the highest levels within PPD and supported by the PPD Global Learning Council, a company-wide group of cross-functional leaders who work to ensure that PPD is an organization of high performance learning.
Rita Bragadesto, Senior PPD Learning Specialist, has also been named one of the 5 Emerging Training Leaders 2020 by Coaching magazine. This honor recognizes training professionals who have worked in the industry for two to ten years and who have demonstrated exceptional leadership skills, business acumen and a training instinct. Bragadesto received its award at Training virtual ceremony on February 8.
PPD is a leading global contract research organization providing comprehensive and integrated drug development, laboratory and lifecycle management services. Our clients include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 26,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a strong commitment to quality to help customers bend the cost and time curve of drug development and Maximize Value by Providing Life-Changing Therapies to Improve Health. For more information, visit www.ppd.com.
This press release contains forward-looking statements. These statements often include words such as âexpectâ, âbelieveâ, âplanâ, âanticipateâ, âestimateâ, âtargetâ and other similar expressions. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results and, therefore, actual results could differ materially from those expressed in forward-looking statements. . Factors that could materially affect these forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changing trends in the biopharmaceutical industry; our ability to keep pace with rapid technological change that could make our services less competitive or obsolete; political, economic and / or regulatory influences and changes; and other factors disclosed in the âRisk Factorsâ section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest annual report on Form 10-K and quarterly report on Form 10 -Q, which is available on our website at https://investors.ppd.com or the SEC website at www.sec.gov. We assume no obligation and disclaim any obligation to revise or update any forward-looking statements, or to make new forward-looking statements, whether as a result of new information, future events or otherwise, unless the law applicable requires it.